Millennium Management LLC Sells 266,668 Shares of Accuray Incorporated (NASDAQ:ARAY)

Millennium Management LLC cut its position in shares of Accuray Incorporated (NASDAQ:ARAY - Free Report) by 79.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 68,814 shares of the medical equipment provider's stock after selling 266,668 shares during the quarter. Millennium Management LLC owned 0.07% of Accuray worth $136,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in ARAY. SG Americas Securities LLC boosted its holdings in Accuray by 37.4% during the fourth quarter. SG Americas Securities LLC now owns 45,079 shares of the medical equipment provider's stock valued at $89,000 after purchasing an additional 12,259 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in Accuray by 10.0% during the fourth quarter. Los Angeles Capital Management LLC now owns 255,378 shares of the medical equipment provider's stock valued at $506,000 after purchasing an additional 23,160 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Accuray by 2.0% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 283,280 shares of the medical equipment provider's stock valued at $561,000 after purchasing an additional 5,421 shares in the last quarter. Intech Investment Management LLC boosted its holdings in Accuray by 104.1% during the fourth quarter. Intech Investment Management LLC now owns 46,680 shares of the medical equipment provider's stock valued at $92,000 after purchasing an additional 23,808 shares in the last quarter. Finally, Perkins Capital Management Inc. boosted its holdings in Accuray by 18.3% during the fourth quarter. Perkins Capital Management Inc. now owns 68,000 shares of the medical equipment provider's stock valued at $135,000 after purchasing an additional 10,500 shares in the last quarter. 64.08% of the stock is owned by institutional investors and hedge funds.

Accuray Price Performance

NASDAQ ARAY traded up $0.01 during trading on Monday, reaching $1.23. 493,523 shares of the company traded hands, compared to its average volume of 751,613. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.88 and a current ratio of 1.62. The stock's 50 day moving average price is $1.50 and its two-hundred day moving average price is $1.84. The company has a market cap of $126.71 million, a price-to-earnings ratio of -24.60 and a beta of 1.30. Accuray Incorporated has a 1-year low of $1.14 and a 1-year high of $2.95.

Accuray (NASDAQ:ARAY - Get Free Report) last posted its earnings results on Wednesday, April 30th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.04. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. The company had revenue of $113.24 million during the quarter, compared to analysts' expectations of $101.53 million. As a group, analysts anticipate that Accuray Incorporated will post 0.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Accuray from a "hold" rating to a "buy" rating in a report on Friday, May 30th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.